OSCEOLA, Wis. and MOUNTAIN VIEW, Calif., July 17, 2014 /PRNewswire-iReach/ -- Surpass, Inc. ("Surpass"), a recognized leader in translational preclinical research, today announced the addition of David Craig, a veteran preclinical scientist and expert veterinary interventionalist, and Benigno Mills, a veterinary surgical and interventional specialist, to the Surpass-Silicon Valley Team. In addition, to better serve our clients, we are pleased to announce that Surpass has launched social media accounts on Twitter, Facebook and Google+ to supplement the existing account on Linked In.
"Surpass is an integrated medical innovation partner for clients in the life-sciences community. These recent strategic hires are evidence of Surpass' commitment to meet our clients' ever-changing needs - rounding out the Scientific and Veterinary Research Team at our West Coast site. With budgets getting tighter and timelines shorter, clients are looking for their CRO partners to do more. They want expertise in study conduct, execution, and reporting while offering flexibility in a compliant environment. The Surpass team offers customized service at our Midwest and West Coast facilities with expert professionals in surgical and interventional services," said Dr. Tim Pelura, President and CEO of Surpass.
David Craig, BS, Director of Operations and Interventional Services, comes to Surpass with more than 17 years of preclinical research experience, working at multiple domestic and international CROs and large medical device and pharmaceutical companies. Benigno Mills, BS, SRS, Interventional and Surgical Specialist, comes with more than five years of preclinical experience at a local contract research organization.
In addition to the recent hires, Surpass is pleased to announce the expansion of our social media platform to include Twitter, Facebook and Google+. "The world of corporate communications has changed. As a valued partner, we want to connect with our clients where they are, on Twitter, Facebook and Google Plus in addition to Linked In. We want to provide value and insight for making their jobs easier," said Dr. Pelura.
Our innovative approach to preclinical research goes beyond the ordinary. We're changing the rules for a better way to get from concept to reality.
Surpass is a trusted contract research organization (CRO) with extensive experience conducting medical device, pharmaceutical, biotech and combination product studies with specialized expertise in surgical and interventional procedures. Our testing services include early feasibility, product development, GLP, and physician/clinical training studies. At Surpass, we provide insightful solutions and support every step of the way, offering expert advice and the level of comprehensive support needed to make your study successful – the first time.
Surpass' breadth of case experience in preclinical studies includes feasibility and safety assessments of ablation systems, vascular grafts, orthopedic prostheses, stents, closure devices, valves, infusion pumps, drug coated balloons, neurostimulators, pharmaceuticals, biologics, imaging systems, cardiac assist devices, and more. Whether you are a startup or an established player, Surpass is uniquely qualified to make your study successful. Contact Surpass today at (651) 433-4277 (Greater Twin Cities) or (650) 477-8267 (Silicon Valley).
Media Contact: Denise Forkey, Surpass, Inc., 650-938-2101, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
|SOURCE Surpass, Inc.|
Copyright©2014 PR Newswire.
All rights reserved